Loading...
In women with advanced breast cancer, metastatic disease commonly causes skeletal-related events (SRE) such as pathologic fracture. The antiresorptive agent zoledronic acid (ZA), a bisphosphonate, reduces risk for SRE in patients with bone metastases, and current guidelines recommend that ZA or pamidronate be administered intravenously every 3 to 4 weeks. In an industry-funded U.S. trial, investigators evaluated the efficacy and safety of ZA administered every 4 weeks versus every 12 weeks for an additional year in 416 women with breast cancer metastatic to bone (mean age, 59; 88% white) who had been receiving standard-of-care ZA or pamidronate during the prior year.
SREs were experienced by 22% and 23% of participants in the 4-week and 12-w…